ZEISS Introduces New Family of OCT Products

  ZEISS Introduces New Family of OCT Products

Modernized new OCT platforms span full spectrum of multi-modality imaging for
glaucoma and retinal disease


Business Wire

CHICAGO & DUBLIN, Calif. & JENA, Germany -- November 10, 2012

Medical technology provider Carl Zeiss Meditec announced today the
introduction of a new family of ZEISS OCT (Optical Coherence Tomography)
products at the 2012 AAO-APAO Joint Meeting in Chicago. The new CIRRUS OCT
family is comprised of two new CIRRUS™ HD-OCT products, models 5000 and 500,
and two new integrated multi-modality OCT and fundus imaging systems, the
CIRRUS™ photo models 800 and 600. The new OCT platforms deliver clinical and
workflow solutions that span the spectrum of care and address specific
workflow and practice needs.

“The new CIRRUS family offers a choice of high-quality ZEISS OCT clinical
solutions for the diagnosis and management of glaucoma and retinal disease
across all levels of care, from comprehensive practices to advanced
subspecialty practices,” says Dr. Ludwin Monz, President and CEO of Carl Zeiss
Meditec AG. “Practitioners can now benefit from diagnostic and workflow
solutions that are tailored specifically for the level of care they provide,
their practice workflow and their case load volumes. The new family of OCT
products enables more practitioners to offer patients a high level of care and
to tailor their investment to their workflow and practice needs.”

The CIRRUS HD-OCT 5000 has been optimized for advanced care with new FastTrac™
retinal tracking that enables the highest resolution B-Scans to be captured in
identical locations from visit to visit providing accurate assessment of
change in targeted pathologies. FastTrac compensates for eye motion during
scanning and can be optionally turned on to assist with poor fixators to
optimize patient throughput.

“With CIRRUS FastTrac, I can place a highest resolution 20x B-Scan precisely
on the area I am treating at each successive visit to see the fine details of
the patient’s response to treatment,” says SriniVas Sadda MD, Director of the
Medical Retina Service at Doheny Eye Institute in Los Angeles, California.
“It’s also very helpful for removing any eye motion from the larger cube scans
without disturbing my patient flow because it works so quickly. My initial
experience is that FastTrac is about 30 percent faster than other tracking
methods I have used.”

Additionally, to meet the needs of advanced care, the CIRRUS HD-OCT 5000 is
configured with the highest resolution visualization capabilities and
sophisticated applications, such as Advanced RPE Analysis to track retinal
pigment epithelial integrity, and Ganglion Cell Analysis to assess
glaucomatous loss in the macula that may not be evident in the peripapillary

Both the CIRRUS HD-OCT 5000 and 500 feature a new modernized OCT platform with
faster processing and OCT camera systems. The new contemporary designs with
larger viewing monitors and wireless keyboard and mouse fit into today’s
modern practice environments. Both models come equipped with ZEISS‘
comprehensive suites of clinical applications for retina and glaucoma and with
time-based historical data and normative data comparison analysis tools to
support efficient and confident patient management.

The CIRRUS HD-OCT 500 has been designed for comprehensive ophthalmic practices
which require essential OCT capabilities and reliability in an easy-to-learn,
easy-to-use instrument. The new faster OCT camera enables quick OCT fundus
image refresh making patient alignment more efficient.

The CIRRUS photo 800 and 600 multi-modality systems combine standard-setting
CIRRUS OCT technology with full-featured mydriatic/non-mydriatic fundus
imaging in one integrated compact and versatile system. Practitioners can
correlate data from high-density OCT cubes, thickness and layer maps with
results from superb color fundus, and angiography images in one imaging
session without the need to move the patient.

“CIRRUS photo gives the opportunity to make complete fundus images without
asking the patient to move from one machine to another,” says Professor
Jean-François Korobelnik, MD. “OCT and color and autofluorescence are very
useful together for the diagnosis and the follow up of macular diseases.”

The CIRRUS photo 800 is designed to support advanced disease management with
fluorescein and ICG angiography, color and fundus autofluorescence imaging,
and OCT technology in an integrated imaging solution. The CIRRUS photo 600
combines non-mydriatic color imaging and OCT with a fundus autofluorescence
option and is designed for comprehensive eye care practices needing efficient
fundus imaging and essential OCT capabilities for assessment and management of
a broad range of conditions.

The CIRRUS HD-OCT 5000 and 500 are immediately available for sale in the US
and other markets. The CIRRUS photo 800 and 600 are to be released globally in
early 2013.

The new CIRRUS OCT family will be on display in ZEISS booth #534 during the
2012 AAO-APAO Joint Meeting in Chicago November 10 to 13, 2012.

Brief profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on TecDax of the
German stock exchange, is one of the world’s leading medical technology
companies. The company supplies innovative technologies and
application-oriented solutions designed to help doctors improve the quality of
life of their patients. It provides complete packages of solutions for the
diagnosis and treatment of eye diseases, including implants and consumables.
The company creates innovative visualization solutions in the field of
microsurgery. The medical technology portfolio of Carl Zeiss Meditec is
rounded off by promising, future-oriented technologies such as intraoperative
radiotherapy. In fiscal year 2010/11 (ended 30 September) the company's around
2,400 employees generated revenue of EUR 759 million.

The head office of Carl Zeiss Meditec is in Jena, Germany. The company has
subsidiaries in Germany and abroad; more than 50 percent of its employees are
based in the USA, Japan, Spain and France. The Center for Research and
Development (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center
for Research and Development in Shanghai, China, strengthen the presence in
these rapidly developing economies. 35 percent of Carl Zeiss Meditec shares
are in free float. The remaining 65 percent are held by Carl Zeiss AG, one of
the world’s leading groups in the optical and optoelectronic industries. Carl
Zeiss offers innovative solutions for the future-oriented markets of Medical
and Research Solutions, Industrial Solutions, Eye Care and Lifestyle Products.
Carl Zeiss AG, Oberkochen, is fully owned by the Carl Zeiss Foundation.

For more information, please go to: www.meditec.zeiss.com


Contact for the press:
Jann Gerrit Ohlendorf, Director Corporate Communications, Carl Zeiss Meditec
+49 36 41 220-331
Contact for investors:
Henriette Meyer, Director Investor Relations, Carl Zeiss Meditec
Press spacebar to pause and continue. Press esc to stop.